Latest Breaking News On - Corneal endothelial cell substitute - Page 1 : comparemela.com

Cellusion Receives U S FDA Orphan Drug Designation for CLS001

Cellusion Receives U S FDA Orphan Drug Designation for CLS001
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesShin hatouDepartment of ophthalmologyIcellusion incKeio university school of medicineDrug administrationDrug designationOrphan drug designationSearch orphan drug designationsCorneal endothelial cell substituteKeio university schoolMore smiles

Cellusion raises 2 83 Billion Yen (21 Million USD) in Series C Round

Cellusion raises 2 83 Billion Yen (21 Million USD) in Series C Round
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hiroaki kobayashiFosun pharmaShin hatouNorio takadaJunichi imotoYoshiharu asaiShigeto shimmuraKeio university hospitalGemseki incInnovation fundHead officeVenture capital co ltdMirai creation fundAxil capital partnersCapital co ltdIcellusion inc

Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy

Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyMinari allendaleHidehito takahashiNoriko takadaHiroto bandoShin hatouMinaris regenerative medicineKeio university school of medicineWorld health organizationIcellusion incUn sustainable development goalsShowa denko materials co ltdKeio university hospitalDepartment of ophthalmologyCorneal endothelial cell substitute

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 f

Celregen Obtains the Exclusive Rights to Develop, Manufacturing and Commercialize CLS001 in Greater China Region; Cellusion Retains Other Regional Rights.The Deal is Worth up to over $100 Million, including Upfront, Development and Sales Milestone Payments, and Tiered Royalties.TOKYO & HANGZHOU, China & SHANGHAI (B.

United statesHong kongWen deyongJoji hayashidaJialei maShin hatouFosun pharmaCui zhipingKeio university school of medicineSinopharm co ltdShanghai fosun pharmaceutical group co ltdFosun health capitalDrug fundHangzhou celregen therapeutics ltdIcellusion incDrug fund of fosun health capital

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region - read this article along with other careers information, tips and advice on BioSpace

United statesHong kongWen deyongShin hatouFosun pharmaCui zhipingKeio university school of medicineSinopharm co ltdShanghai fosun pharmaceutical group co ltdFosun health capitalDrug fundHangzhou celregen therapeutics ltdIcellusion incDrug fund of fosun health capitalFosun new drug fundKeio university hospital